enGene Holdings Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
3.660
+0.070 (1.95%)
Jun 27, 2025, 4:00 PM - Market closed
Company Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer.
Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG).
enGene Holdings Inc. is based in Montreal, Canada.
enGene Holdings Inc.
| Country | Canada |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Ronald H. Cooper |
Contact Details
Address: 4868 Rue Levy, Suite 220 Montreal, QC H4R 2P1 Canada | |
| Phone | 514 332 4888 |
| Website | engene.com |
Stock Details
| Ticker Symbol | ENGN |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001980845 |
| CUSIP Number | 46429B226 |
| ISIN Number | CA29286M1059 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ronald H. W. Cooper | President, Chief Executive Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2025 | 10-Q | Quarterly Report |
| Jun 12, 2025 | 8-K | Current Report |
| Jun 10, 2025 | 8-K | Current Report |
| Jun 9, 2025 | 8-K | Current Report |
| Jun 4, 2025 | 8-K | Current Report |
| May 9, 2025 | ARS | Filing |
| May 9, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 10, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 10, 2025 | 10-Q | Quarterly Report |
| Mar 10, 2025 | 8-K | Current Report |